TICO Study: TDF-containing HAART vs 3TC-containing HAART in ARV-naive HIV/HBV coinfected patients
•Randomized Thai trial (1:1:1) of 3TC vs TDF vs 3TC/TDF within a EFV-based HAART regimen (n=36)
•Hepatic flare in 9 (25%) patients, 4 of whom had HBe-Ag loss (2 with HBsAg seroconversion)
•1 died of hepatic decompensation
•Detectable HBV viremia at Week 48 is a risk factor for future HBV resistance development (2 cases of 3TC resistance in 3TC only group)
•Good initial anti-HBV response for all 3 arms but more resistance in the 3TC arm at wk 48
Matthews G, et al. 4th IAS, Sydney 2007, #TUAB205
70
60
50
40
30
20
10
0
Percent
<2.3 log c/ml
2.3–3 log c/ml
>3 log c/ml
3TC
TDF
3TC/TDF
p=0.016
On treatment
3TC
TDF
3TC/TDF
Total
HBeAg loss
3 (33%)
1 (17%)
3 (43%)
7 (32%)
Anti-HBe Seroconversion
1 (11%)
1 (17%)
3 (43%)
6 (27%)
HBsAg loss
1 (8%)
1 (8%)
1 (9%)
3 (8%)
HIV suppression at Week 48